There are 2789 resources available
748P - Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)
Presenter: Margarita Romeo Marin
Session: ePoster Display
749P - Cardiotoxicity in patients treated with PARP-inhibitors
Presenter: Mariola Blanco Clemente
Session: ePoster Display
793P - Comparison of two high-dose rate (HDR) brachytherapy regimens in treatment of cervical cancer
Presenter: Abhishek Krishna
Session: ePoster Display
Resources:
Abstract
794P - Comparative study of effectiveness of Pap smear and visual inspection with acetic acid for screening of premalignant and malignant lesion of cervix in a tertiary care setup
Presenter: Meena Kakollu
Session: ePoster Display
796P - Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111
Presenter: Vicky Makker
Session: ePoster Display
798P - A phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001
Presenter: Lorena Fariñas-Madrid
Session: ePoster Display
912P - Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115)
Presenter: Viktor Gruenwald
Session: ePoster Display
913P - Apatinib for heavily pretreated recurrent and/or metastatic head and neck squamous cell carcinoma: Updated analysis
Presenter: kunyu yang
Session: ePoster Display